85 results about "Benign prostatic hyperplasia (BPH)" patented technology

This invention relates to a non-invasive predictive kit and method for the progression of benign prostatic hyperplasia (BPH) based on prostatic fluid. The invention provides the application of FGF9 as a non-invasive predictive biomarker for the progression of BPH based on prostatic fluid, wherein the concentration of FGF9 in prostatic fluid serves as an indicator of BPH progression. The invention also provides a method for detecting the concentration of FGF9 in prostatic fluid for non-disease diagnostic purposes. Compared with existing technologies, the non-invasive BPH detection method based on prostatic fluid of this invention has advantages such as non-invasiveness, accuracy, simplicity, practicality, and scalability, and is expected to be widely used in the clinical diagnosis and treatment of prostate diseases.

The invention provides application of Fe3O4 nanoparticles in preparation of a medicine for treating benign prostatic hyperplasia, and relates to the technical field of biological medicines. The invention further discloses application of the Fe3O4 nano-particles in preparation of a medicine for treating benign prostatic hyperplasia. The research result of the invention emphasizes that the ferroferric oxide nanoparticles are a promising candidate drug for targeted therapy of BPH and related prostate diseases, and new possibility is provided for treatment intervention of urinary surgery. The inventor studies the effect of the Fe3O4 nanoparticles in inhibiting benign prostatic hyperplasia. Results of the inventor show that the nanoparticles not only effectively reduce the proliferation rate of prostate cells, but also improve related biochemical indexes. Therefore, the polypeptide has potential application in treatment of prostatic hyperplasia.

Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue are disclosed. A system includes a sustained release solid formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising the sustained release solid formulation to the prostate.

The invention belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to application of a detection reagent for GDF15 protein in extracellular vesicles in preparation of a prostate cancer diagnosis and / or staging kit. According to the invention, enrichment and proteomics detection are carried out on plasma EVs of patients with prostatic cancer (PCa) and benign prostatic hyperplasia (BPH), and through bioinformatics analysis, a potential EV protein marker GDF15 which can be used for early diagnosis of PCa is screened for the first time. The GDF15 protein is verified in a plurality of groups of new clinical queues by further adopting an immunological technology and a targeted quantitative mass spectrometry technology, and the distinguishing ability of the GDF15 protein to PCa and BPH and the distinguishing ability of the GDF15 protein to different PCa stages are determined. The method is expected to promote noninvasive precise diagnosis of clinical PCa, and has a good application prospect.

The invention provides a pharmaceutical composition and application thereof in preparation of a compound preparation, and belongs to the field of medicines. The pharmaceutical composition comprises a potassium ion channel opener, a 5 alpha-reductase inhibitor and a phosphodiesterase 5 inhibitor. The pharmaceutical composition can synergistically promote treatment of androgen dependent diseases or prevention of complications, and by taking the pharmaceutical composition of minoxidil, finasteride and tadalafil as an example, the effects in a benign prostatic hyperplasia rat model and an androgenic alopecia mouse model are verified, which indicates that the minoxidil, finasteride and tadalafil have a synergistic interaction effect, and the pharmaceutical composition can be used for treating the androgen dependent diseases or preventing the complications. Good clinical application prospects are realized.

The invention relates to a balloon catheter for transurethral use, having a proximal region (2) comprising an at least single-lumen catheter shaft (4) with an inflation lumen and an inflatable balloon (5) connected to the distal end of the inflation lumen in a fluid-permeable manner, and a distal region (3) comprising a distal shaft (7) and a distal tip (9). The balloon (5) is coated with a medication and a placement aid (10) is provided at least in the proximal region (2). The placement aid (10) is tubular at least in the region of the balloon (5), and the tubular section has a length at least equal to the length of the balloon (5). The balloon catheter according to the invention allows the conservative treatment of benign prostatic hyperplasia without the use of additional imaging techniques.

Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue are disclosed. A system includes a sustained release solid formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising the sustained release solid formulation to the prostate.

A method for determining the presence of prostate cancer in a subject, the method comprising the steps of: (i) determining the level of one or more biomarkers in a sample from the subject; (ii) compar

The invention belongs to the technical field of traditional Chinese medicine, and relates to a pine pollen compound fermentation composition and a preparation method and application thereof, and the preparation method comprises the following steps: (1) water extraction; (2) enzymolysis; (3) sterilizing; (4) fermenting; (5) sterilizing; and (6) drying to obtain the pine pollen compound fermentation composition. The pine pollen compound fermentation composition disclosed by the invention can promote rapid dissolution of key active ingredients and enrich the content of active ingredients, namely flavone and polysaccharide, for improving benign prostatic hyperplasia in the raw materials, so that a foundation is laid for the benign prostatic hyperplasia improvement effect of a compound fermentation product; the inherent bitter taste of the pine pollen and other raw materials is effectively reduced, and the palatability of the product and the pleasure of consumers are improved; animal experiments prove that the traditional Chinese medicine composition has the beneficial effect of improving benign prostatic hyperplasia.

Computer-implemented methods for providing interactive electronic treatment assistance for benign prostatic hyperplasia and advanced prostate cancer are disclosed. The methods can include automatically sending, by a disease and disorder treatment device, an electronic pathway sign-up link to a smart mobile device. The method can include sending a plurality of inquiries about the BPH condition and / or the advanced prostate cancer condition, to the smart mobile device. The method can include receiving a plurality of patient responses from the smart mobile device. The method can include processing and storing the plurality of patient responses. The method can include providing, by the disease and disorder treatment device, patient education about various treatment therapies for advanced prostate cancer. The method can include automatically monitoring a patient having the advanced prostate cancer condition during the various treatment therapies. The method can include intervening with the various treatment therapies using the smart mobile device.

The invention relates to the technical field of biology, in particular to application of a prostate intermediate state cell and an inhibitor of the prostate intermediate state cell, and discloses application of the prostate intermediate state cell and an organ or tissue comprising the prostate intermediate state cell as a target in screening of drugs for treating prostatitis or prostatic hyperplasia. The prostate intermediate state cell inhibitor is applied to preparation of a medicine for treating prostatitis or benign prostatic hyperplasia; the inhibitor of the prostate intermediate state cells comprises one or more of a GRN signal channel inhibitor and a Sema4 signal channel agonist. The application provides a new therapeutic target for treatment of prostatitis or benign prostatic hyperplasia and drug screening, and provides a potential strategy for clinical treatment of prostatitis and benign prostatic hyperplasia.

This invention discloses the application of two dipeptides in the preparation of a diagnostic kit for differentiating prostate cancer from benign prostatic hyperplasia (BPH). The invention reveals that the combination of the dipeptides H-Asp-Phe-OH (DF) and H-Leu-Ala-OH (LA) with prostate-specific antigen (PSA) has high diagnostic value in differentiating prostate cancer from BPH, with a high accuracy rate. The combined diagnostic effect of these three peptides is significantly better than that of PSA alone in differentiating between prostate cancer and BPH, showing promise for development into a diagnostic kit for differentiating prostate cancer from BPH.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and / or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

The application discloses application of CFHR5 protein in preparation of a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia. It is found by the application that the CFHR5 protein has high diagnostic value for distinguishing prostate cancer and benign prostatic hyperplasia, the accuracy of diagnosis and distinction is high, and the CFHR5 protein has the prospect of being developed into a kit for diagnosing and distinguishing prostate cancer and benign prostatic hyperplasia.

The invention provides a bisphenol A induced rat benign prostatic hyperplasia model and a construction method, and relates to the technical field of animal models. The method comprises the following steps: S1, selecting rats which are 8-9 months old and 9-10 weeks old, and adaptively feeding the rats in a suitable environment for 7 days or more; s2, jointly applying high-fat feed and bisphenol A to the adaptively fed rats to induce benign prostatic hyperplasia; the induction time is 60-80 days, and performing biological index evaluation after the induction is completed. The exposure level of low-dose BPA adopted by the invention is closer to the actual environment exposure level of people, and a main exposure way is simulated through oral gavage. The model constructed by the method can better simulate the real process of chronic and low-dose exposure pathopoiesis of the environmental endocrine disrupter in etiology, and provides an experimental tool with more practical significance for related risk evaluation.

1. The name of the design product: hot steam treatment equipment. 2. The use of the design product: used with the prostate hot steam treatment instrument to relieve symptoms and obstruction related to benign prostatic hyperplasia (BPH). 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention relates to a compound as shown in a formula (I) or a salt or a solvate thereof, and also relates to a preparation method of the compound as shown in the formula (I), a pharmaceutical composition containing the compound as shown in the formula (I), and application of the compound as shown in the formula (I) or the pharmaceutical composition containing the compound as shown in the formula (I) in preparation of medicines for treating alopecia and benign prostatic hyperplasia. Through injection administration, the administration effect can be maintained for a long time, and the long-acting pharmaceutical property is ideal.

The present disclosure is directed to a method of treating overactive bladder symptoms in men with benign prostatic hyperplasia comprising orally administering to a subject in need thereof an amount of from about 60 mg to about 90 mg (e.g., about 75 mg) of vibegron per day.

The invention provides an application of an aromatase gene CYP19A1 methylation level in evaluation of benign prostatic hyperplasia progress degree. The traditional Chinese medicine composition is used for treating benign prostatic hyperplasia patients from early progression; whether methylation and demethylation occur in CpG islands in promoter regions of aromatase genes CYP19A1 in prostate tissues of bladder cancer patients and elderly benign prostatic hyperplasia patients who are age-matched and subjected to radical bladder resection and prostatic resection are detected and analyzed, and whether methylation and demethylation occur in the CpG islands in the promoter regions of the aromatase genes CYP19A1 in the prostate tissues or not is judged; according to the present invention, the CYP19A1 gene methylation level is low and the CYP19A1 gene demethylation level is high in the prostate tissue of the early stage progression BPH patient, and the aromatase expression of the coding protein of the CYP19A1 gene is up-regulated, such that the aromatase gene CYP19A1 methylation change is related to the benign prostatic hyperplasia progress, and the new thought is provided for the risk stratification of the benign prostatic hyperplasia disease;

The present invention relates to compounds that are activators of the Alpha1A-Adrenergic Receptor (α1A-AR) and methods of using such compounds: for treating neurological conditions, for cardio-protection, and for treating other conditions. In certain embodiments, the α1A-AR activator compound is a compound of Formula I. In certain embodiments, the neurological condition is Alzheimer's disease, benign prostatic hyperplasia, memory loss, depression, or Parkinson's disease.

The present invention relates to a composition, a kit, and an information providing method for diagnosing prostate cancer using the methylation level of CpG regions. By using the composition, the kit, and the information providing method according to the present invention, it is possible to distinguish between prostate cancer and benign prostatic hyperplasia, and thereby diagnose prostate cancer not only quickly and accurately, but also early.

Embodiments of the present invention provide a method of treating a stricture in a nonvascular body lumen such as urethral strictures, benign prostatic hyperplasia (BPH) strictures, ureteral strictures, esophageal strictures, sinus strictures, and biliary tract strictures. Embodiments of the present invention provide a method for treating at least one of benign prostatic hyperplasia (BPH), prostate cancer, asthma, and chronic obstructive pulmonary disease (COPD). The method can include delivering, for example, via drug coated balloon catheters, anti-inflammatory and anti-proliferative drugs (e.g., rapamycin, paclitaxel, and their analogues) and one or more additives.

The dilatation balloon device comprises a catheter, a first balloon body, a protruding structure and a connecting piece, the catheter extends in the front-back direction, a first channel penetrating in the front-back direction is formed in the catheter, the first balloon body is arranged at the front end of the catheter, the front end of the first channel is communicated with the interior of the first balloon body, and the rear end of the first channel is communicated with a pressurizing device. The protruding structures are arranged on the outer surface of the first bag body in a protruding mode and distributed in a long shape extending in the front-back direction, in a projection view perpendicular to the front-back direction, the protruding structures are distributed on the periphery of the first bag body in a non-centrosymmetric mode, and the connecting piece is arranged at the rear end of the catheter and used for communicating the first channel with the pressurizing device. In the invention, the bulge structure can apply pressure to the affected part in a targeted manner, so that the affected part is cracked before other tissues in the bulge process of the first capsule body, and the treatment purpose is achieved. Therefore, the treatment accuracy can be improved, unnecessary tearing of healthy tissues is reduced, the complication risk is reduced, and the minimally invasive treatment requirements of diseases such as benign prostatic hyperplasia are met.

The invention provides application of TRMT61A as a target spot in preparation of a medicine for preventing or treating benign prostatic hyperplasia. The TRMT61A is specifically targeted through shRNA, pathogenic signals are blocked from the post-transcriptional level, accurate intervention on benign prostatic hyperplasia is achieved, dependence on androgen pathways is completely avoided, unavoidable sexual dysfunction and other serious side effects of traditional drugs are fundamentally avoided, and the life quality of patients is remarkably improved.

Disclosed herein is a benign prostatic hyperplasia treatment device. The benign prostatic hyperplasia treatment device includes: anchor assemblies including a first anchor arranged at the outer surface of the prostate gland, which obstructs the prostatic urethra, a second anchor arranged inside the prostate gland to be opposed to the first anchor, and a ligature connecting the first anchor and the second anchor with each other so that the second anchor compresses the prostate tissue to secure the opening of the prostatic urethra; and a sheath inserted into the urethra and having a needle, which guides the anchor assembly to be deployed at the prostate gland.

The traditional Chinese medicine composition is prepared from the following raw materials: astragalus membranaceus, herba artemisiae anomalae, pollen typhae, rhizoma dioscoreae septemlobae, stiff silkworm, kelp, cinnamon, curcuma zedoary, euphorbia helioscopia, tortoise plastron and liquorice. According to the traditional Chinese medicine composition or the extract of the traditional Chinese medicine composition provided by the invention, under the guidance of a new thought of prostate meridian and collateral qi and blood differentiation, inherent physiological differences of different regions of the prostate are fully considered, pathological characteristics and pathogenesis of diseases are discriminated on the basis, and a new traditional Chinese medicine formula aiming at prostate lesions is constructed and formed; the traditional Chinese medicine formula especially aims at benign prostatic hyperplasia lesions.

The present invention discloses a composition, a preparation and a preparation method and application thereof for treating benign prostatic hyperplasia, relating to the technical field of traditional Chinese medicine. The composition comprises the following components: Flemingia philippinensis Merr. ex Rolfe, Curcuma zedoaria (Christm.) Rosc., Eucommia ulmoides Oliv., Achyranthes bidentata Blume, Codonopsis pilosula (Franch.) Nannf., Astragalus membranaceus (Fisch.) Bunge, Cinnamomum cassia Presl, Curculigo orchioides Gaertn., Epimedium brevicornu Maxim., Phellodendron amurense Rupr., Poria cocos (Schw.) Wolf, Paeonia suffruticosa Andr., Paeonia lactiflora Pall. and Prunus persica (L.) Batsch. The preparation is prepared from the composition as a traditional Chinese medicine raw material medicine, and the preparation method comprises: mixing the raw material medicines, soaking in water, decocting and taking the medicinal liquid, and further processing the obtained medicinal liquid into a common traditional Chinese medicine preparation according to a conventional process. In the treatment process of benign prostatic hyperplasia with the traditional Chinese medicine composition and the preparation thereof, patients rarely have situations such as orthostatic hypotension and erectile dysfunction, and are superior to the treatment with pure western medicine in relieving the prostate symptoms of patients, improving the quality of life and improving the lower urinary tract symptoms, and moreover, the effects of relieving the symptoms of soreness and weakness of the waist and knees, fatigue and weakness, and aversion to cold and cold limbs are obvious.

In some aspects thereof, the present invention discloses compositions and methods for treating premature ejaculation utilizing tamsulosin at a 0.2 milligram dose administered orally or transdermally every 48 hours. Tamsulosin functions as a selective antagonist of alpha-1a and 1b adrenergic as well as 5HT1A serotonergic receptors implicated in seminal emission pathways. The quantity and frequency of dosing provides an optimal degree of reversible receptor blockade to mildly inhibit sympathetic and serotonergic mediated smooth muscle contraction kinetics governing seminal fluid secretion and transport. This marginally suppresses rate of emission to prolong intercourse without profoundly arresting physiological processes underlying ejaculation.

The invention provides a preparation method of the diterpenoid composition. The method comprises the following steps: extracting a rubus chingii material to obtain an extract composition; suspending the extract composition, and performing liquid-liquid extraction on the suspension to obtain a target extraction part; adsorbing and separating the target extraction part through macroporous resin, and eluting to obtain a target fraction; eluting the target fraction to obtain a target eluate; and drying the target eluate to obtain a powder product. Also provided are a diterpenoid composition obtained by the method, an oral composition comprising the diterpenoid composition, a composition comprising at least one diterpenoid extract of rubus chingii, the use of the composition in the preparation of a medicament for the treatment of benign prostatic hyperplasia (BPH) in a subject, and a method of treating BPH in a subject.